IBOV 173,714.08 ▼ 0.06% IPSA 10,886.14 ▼ 0.56% IPC MEX 66,615.43 ▲ 0.39% MERVAL 3,199,934 ▲ 0.46% COLCAP 2,298.34 ▲ 0.58% BVL PERÚ 57,220.16 — — USD/BRL5.11▲ 0.19% USD/MXN17.53▲ 0.59% USD/CLP931.20▲ 0.67% USD/COP3,251▲ 0.61% USD/PEN3.39▲ 0.21% USD/ARS1,478▲ 0.17% USD/UYU40.23▲ 1.74% USD/PYG6,032▲ 1.81% USD/BOB10.65▲ 4.37% USD/DOP58.24▲ 1.37% USD/CRC446.12▲ 1.44% USD/GTQ7.62▲ 2.73% USD/HNL26.73▲ 1.94% USD/NIO36.62▲ 0.34% USD/VES730.65▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.59▲ 0.87% USD/TTD6.74▲ 1.70% EUR/BRL5.84▲ 0.16% BRENT 88.10 ▲ 4.59% WTI 81.78 ▲ 3.58% IRON ORE 161.91 — — COPPER 6.27 ▼ 0.49% GOLD 4,019 ▲ 0.83% SILVER 56.33 ▲ 0.77% SOY 1,203 ▲ 0.67% CORN 467.50 ▲ 5.89% WHEAT 682.75 ▲ 1.19% COFFEE 304.70 ▼ 5.17% SUGAR 14.82 ▲ 2.63% ORANGE JUICE 139.35 ▲ 4.15% COTTON 78.93 ▲ 1.60% COCOA 5,753 ▲ 10.30% BEEF 220.70 ▼ 2.81% CATTLE 339.35 ▼ 2.09% LITHIUM 68.38 ▼ 0.70% PETR4 40.90 ▲ 2.53% VALE3 72.94 ▼ 0.05% ITUB4 41.96 ▼ 1.39% BBDC4 18.29 ▼ 0.65% ABEV3 15.63 ▲ 0.19% BBAS3 20.49 ▼ 1.30% B3SA3 15.20 ▼ 1.23% WEGE3 43.63 ▲ 0.32% PRIO3 57.85 ▲ 1.87% SUZB3 41.93 ▲ 0.55% RENT3 38.23 ▼ 1.62% AZZA3 18.59 ▲ 0.32% CSAN3 3.84 ▼ 1.03% RAIZ4 0.29 — 0.00% PCAR3 2.60 ▲ 0.39% GMAT3 3.88 ▼ 1.02% PSSA3 55.14 ▼ 0.14% CVCB3 1.22 ▼ 9.63% POSI3 3.80 ▼ 2.06% SLCE3 13.53 ▼ 0.59% NATU3 8.55 ▼ 0.12% BRKM5 6.19 ▲ 1.48% RANI3 7.95 ▼ 1.61% CSNA3 5.05 ▼ 0.98% CMIN3 5.33 ▼ 2.20% USIM5 8.23 ▲ 4.18% GGBR4 24.04 ▲ 0.54% ENEV3 25.68 ▼ 1.04% CPFE3 46.87 ▼ 0.68% CMIG4 11.12 ▲ 0.27% EQTL3 39.50 ▼ 0.88% LREN3 13.42 ▼ 1.69% VIVT3 35.52 ▲ 0.14% RAIL3 13.70 ▼ 1.65% KLABIN 17.58 ▲ 1.27% RAIA DROGASIL 18.55 ▲ 0.16% RDOR3 35.78 ▼ 0.25% HAPV3 11.38 ▲ 3.93% FLRY3 16.59 ▲ 1.04% SMTO3 15.45 ▼ 1.72% UGPA3 32.07 ▲ 0.25% VBBR3 34.92 ▲ 1.60% BBSE3 41.12 ▼ 0.15% BPAC11 56.18 ▼ 0.72% CURY3 30.67 ▼ 1.98% AERI3 2.02 — 0.00% VIVARA 22.44 ▼ 3.90% COMPASS 24.88 ▼ 0.12% VAMOS 3.17 ▲ 0.32% SANB11 26.65 ▼ 0.67% ASAI3 8.50 ▼ 0.70% SBSP3 29.22 ▼ 0.27% WALMEX 49.52 ▼ 0.08% GMEXICO 200.05 ▲ 0.41% FEMSA 225.68 ▲ 0.28% CEMEX 22.69 ▼ 0.40% GFNORTE 181.34 ▲ 0.53% BIMBO 58.00 ▲ 0.14% TELEVISA 9.57 ▲ 0.63% AMX 23.00 ▲ 0.97% GAP 386.00 ▼ 1.47% ASUR 279.71 ▼ 0.44% OMA 230.06 ▼ 1.30% KOF 181.10 ▲ 1.20% GRUMA 287.32 ▲ 0.34% KIMBER 38.67 ▼ 0.28% SQM-B 65,450 ▼ 0.91% COPEC 6,250 ▲ 2.02% BSANTANDER 77.00 ▼ 1.48% FALABELLA 5,835 ▼ 0.31% ENELAM 84.04 ▼ 0.90% CENCOSUD 1,995 ▼ 0.50% CMPC 1,070 ▼ 0.37% BANCO CHILE 188.50 ▼ 0.20% LATAM AIR 24.76 ▼ 2.52% YPF 77,900 ▲ 2.40% GGAL 7,860 ▼ 0.06% PAMPA 5,170 ▲ 1.17% TXAR 665.00 ▲ 0.45% ALUAR 949.50 ▲ 1.01% TGS 9,370 ▼ 0.16% CEPU 2,264 ▲ 0.18% MIRGOR 16,875 ▲ 0.75% COME 43.84 ▼ 1.39% LOMA NEGRA 3,535 ▼ 0.63% BYMA 299.00 ▼ 0.83% TELECOM ARG 4,150 ▼ 0.72% ECOPETROL 16.09 ▲ 1.84% BANCOLOMBIA 80.41 ▲ 1.18% GRUPO AVAL 4.92 ▼ 1.01% CREDICORP 390.70 ▲ 0.84% SOUTHERN COPPER 172.48 ▼ 1.81% BUENAVENTURA 30.24 ▲ 0.23% MERCADOLIBRE 1,814 ▼ 2.34% NUBANK 13.59 ▼ 1.45% XP 16.67 ▼ 0.06% PAGSEGURO 9.04 ▼ 1.20% STONE 11.15 ▼ 0.45% GLOBANT 32.23 ▲ 0.09% TECNOGLASS 46.48 ▼ 0.75% GAP AIRPORT 220.91 ▼ 1.94% ASUR 279.71 ▼ 0.44% OMA AIRPORT 105.31 ▼ 1.77% AMX ADR 26.27 ▲ 0.50% FEMSA ADR 129.02 ▼ 0.36% CEMEX ADR 12.98 ▼ 0.92% PETROBRAS ADR 17.97 ▲ 2.86% VALE ADR 14.19 ▼ 0.21% ITAU ADR 8.21 ▼ 1.14% SANTANDER BR 5.24 ▼ 1.04% AMBEV ADR 3.03 ▼ 0.66% CSN 0.99 ▼ 0.89% GERDAU 4.73 ▲ 0.11% LATAM ADR 52.56 ▼ 1.17% BTC 64,147 ▲ 0.39% ETH 1,844 ▲ 0.16% SOL 74.82 ▼ 0.26% XRP 1.09 ▼ 0.06% BNB 570.53 ▲ 0.49% ADA 0.16 ▼ 1.23% DOGE 0.07 ▼ 0.40% AVAX 6.56 ▼ 0.30% LINK 8.30 ▲ 0.53% DOT 0.83 ▼ 1.99% LTC 45.98 ▲ 1.85% BCH 220.40 ▲ 0.30% TRX 0.32 ▲ 0.40% XLM 0.19 ▲ 0.47% HBAR 0.07 ▲ 1.03% NEAR 1.91 ▼ 0.75% ATOM 1.49 ▼ 1.36% AAVE 88.56 ▼ 1.55% SELIC 14.25% EMBRAER 81.75 ▼ 0.02% EMBRAER ADR 64.09 ▼ 0.44% JBS 11.91 ▼ 1.00% JBS BDR 60.20 ▼ 2.11% MBRF3 15.03 ▼ 1.70% MBRFY 2.90 ▼ 1.02% INTER 5.37 ▼ 3.07% EGX 52,928 ▲ 0.70% USD/ZAR16.48— 0.00% USD/NGN1,378▼ 0.20% NIKKEI 64,141 ▼ 4.03% CSI300 4,529 ▼ 3.60% HSI 24,562 ▼ 1.78% NIFTY 24,334 ▲ 1.09% KOSPI 6,821 ▼ 6.37% JCI 6,176 ▲ 1.10% USD/JPY162.35▼ 0.03% USD/CNY6.78▲ 0.01% DAX 24,831 ▼ 0.34% CAC 8,339 ▼ 0.47% FTSE 10,600 ▲ 0.27% MIB 51,882 ▼ 0.94% IBEX 19,217 ▼ 0.45% STOXX 641.53 ▼ 0.34% EUR/USD1.14▲ 0.04% GBP/USD1.35▼ 0.66% SPX 7,458 ▼ 1.01% DJI 52,146 ▼ 0.77% NDX 28,593 ▼ 1.49% RUT 2,962 ▼ 0.42% TSX 35,264 ▼ 0.22% VIX 18.77 ▲ 12.19% USD/CAD1.40— 0.00% US10Y 4.5410 ▼ 0.61% IBOV 173,714.08 ▼ 0.06% IPSA 10,886.14 ▼ 0.56% IPC MEX 66,615.43 ▲ 0.39% MERVAL 3,199,934 ▲ 0.46% COLCAP 2,298.34 ▲ 0.58% BVL PERÚ 57,220.16 — — USD/BRL 5.11 ▲ 0.19% USD/MXN 17.53 ▲ 0.59% USD/CLP 931.20 ▲ 0.67% USD/COP 3,251 ▲ 0.61% USD/PEN 3.39 ▲ 0.21% USD/ARS 1,478 ▲ 0.17% USD/UYU 40.23 ▲ 1.74% USD/PYG 6,032 ▲ 1.81% USD/BOB 10.65 ▲ 4.37% USD/DOP 58.24 ▲ 1.37% USD/CRC 446.12 ▲ 1.44% USD/GTQ 7.62 ▲ 2.73% USD/HNL 26.73 ▲ 1.94% USD/NIO 36.62 ▲ 0.34% USD/VES 730.65 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.59 ▲ 0.36% USD/TTD 6.74 ▲ 1.17% EUR/BRL 5.84 ▲ 0.16% BRENT 88.10 ▲ 4.59% WTI 81.78 ▲ 3.58% IRON ORE 161.91 — — COPPER 6.27 ▼ 0.49% GOLD 4,019 ▲ 0.83% SILVER 56.33 ▲ 0.77% SOY 1,203 ▲ 0.67% CORN 467.50 ▲ 5.89% WHEAT 682.75 ▲ 1.19% COFFEE 304.70 ▼ 5.17% SUGAR 14.82 ▲ 2.63% ORANGE JUICE 139.35 ▲ 4.15% COTTON 78.93 ▲ 1.60% COCOA 5,753 ▲ 10.30% BEEF 220.70 ▼ 2.81% CATTLE 339.35 ▼ 2.09% LITHIUM 68.38 ▼ 0.70% PETR4 40.90 ▲ 2.53% VALE3 72.94 ▼ 0.05% ITUB4 41.96 ▼ 1.39% BBDC4 18.29 ▼ 0.65% ABEV3 15.63 ▲ 0.19% BBAS3 20.49 ▼ 1.30% B3SA3 15.20 ▼ 1.23% WEGE3 43.63 ▲ 0.32% PRIO3 57.85 ▲ 1.87% SUZB3 41.93 ▲ 0.55% RENT3 38.23 ▼ 1.62% AZZA3 18.59 ▲ 0.32% CSAN3 3.84 ▼ 1.03% RAIZ4 0.29 — 0.00% PCAR3 2.60 ▲ 0.39% GMAT3 3.88 ▼ 1.02% PSSA3 55.14 ▼ 0.14% CVCB3 1.22 ▼ 9.63% POSI3 3.80 ▼ 2.06% SLCE3 13.53 ▼ 0.59% NATU3 8.55 ▼ 0.12% BRKM5 6.19 ▲ 1.48% RANI3 7.95 ▼ 1.61% CSNA3 5.05 ▼ 0.98% CMIN3 5.33 ▼ 2.20% USIM5 8.23 ▲ 4.18% GGBR4 24.04 ▲ 0.54% ENEV3 25.68 ▼ 1.04% CPFE3 46.87 ▼ 0.68% CMIG4 11.12 ▲ 0.27% EQTL3 39.50 ▼ 0.88% LREN3 13.42 ▼ 1.69% VIVT3 35.52 ▲ 0.14% RAIL3 13.70 ▼ 1.65% KLABIN 17.58 ▲ 1.27% RAIA DROGASIL 18.55 ▲ 0.16% RDOR3 35.78 ▼ 0.25% HAPV3 11.38 ▲ 3.93% FLRY3 16.59 ▲ 1.04% SMTO3 15.45 ▼ 1.72% UGPA3 32.07 ▲ 0.25% VBBR3 34.92 ▲ 1.60% BBSE3 41.12 ▼ 0.15% BPAC11 56.18 ▼ 0.72% CURY3 30.67 ▼ 1.98% AERI3 2.02 — 0.00% VIVARA 22.44 ▼ 3.90% COMPASS 24.88 ▼ 0.12% VAMOS 3.17 ▲ 0.32% SANB11 26.65 ▼ 0.67% ASAI3 8.50 ▼ 0.70% SBSP3 29.22 ▼ 0.27% WALMEX 49.52 ▼ 0.08% GMEXICO 200.05 ▲ 0.41% FEMSA 225.68 ▲ 0.28% CEMEX 22.69 ▼ 0.40% GFNORTE 181.34 ▲ 0.53% BIMBO 58.00 ▲ 0.14% TELEVISA 9.57 ▲ 0.63% AMX 23.00 ▲ 0.97% GAP 386.00 ▼ 1.47% ASUR 279.71 ▼ 0.44% OMA 230.06 ▼ 1.30% KOF 181.10 ▲ 1.20% GRUMA 287.32 ▲ 0.34% KIMBER 38.67 ▼ 0.28% SQM-B 65,450 ▼ 0.91% COPEC 6,250 ▲ 2.02% BSANTANDER 77.00 ▼ 1.48% FALABELLA 5,835 ▼ 0.31% ENELAM 84.04 ▼ 0.90% CENCOSUD 1,995 ▼ 0.50% CMPC 1,070 ▼ 0.37% BANCO CHILE 188.50 ▼ 0.20% LATAM AIR 24.76 ▼ 2.52% YPF 77,900 ▲ 2.40% GGAL 7,860 ▼ 0.06% PAMPA 5,170 ▲ 1.17% TXAR 665.00 ▲ 0.45% ALUAR 949.50 ▲ 1.01% TGS 9,370 ▼ 0.16% CEPU 2,264 ▲ 0.18% MIRGOR 16,875 ▲ 0.75% COME 43.84 ▼ 1.39% LOMA NEGRA 3,535 ▼ 0.63% BYMA 299.00 ▼ 0.83% TELECOM ARG 4,150 ▼ 0.72% ECOPETROL 16.09 ▲ 1.84% BANCOLOMBIA 80.41 ▲ 1.18% GRUPO AVAL 4.92 ▼ 1.01% CREDICORP 390.70 ▲ 0.84% SOUTHERN COPPER 172.48 ▼ 1.81% BUENAVENTURA 30.24 ▲ 0.23% MERCADOLIBRE 1,814 ▼ 2.34% NUBANK 13.59 ▼ 1.45% XP 16.67 ▼ 0.06% PAGSEGURO 9.04 ▼ 1.20% STONE 11.15 ▼ 0.45% GLOBANT 32.23 ▲ 0.09% TECNOGLASS 46.48 ▼ 0.75% GAP AIRPORT 220.91 ▼ 1.94% ASUR 279.71 ▼ 0.44% OMA AIRPORT 105.31 ▼ 1.77% AMX ADR 26.27 ▲ 0.50% FEMSA ADR 129.02 ▼ 0.36% CEMEX ADR 12.98 ▼ 0.92% PETROBRAS ADR 17.97 ▲ 2.86% VALE ADR 14.19 ▼ 0.21% ITAU ADR 8.21 ▼ 1.14% SANTANDER BR 5.24 ▼ 1.04% AMBEV ADR 3.03 ▼ 0.66% CSN 0.99 ▼ 0.89% GERDAU 4.73 ▲ 0.11% LATAM ADR 52.56 ▼ 1.17% BTC 64,147 ▲ 0.39% ETH 1,844 ▲ 0.16% SOL 74.82 ▼ 0.26% XRP 1.09 ▼ 0.06% BNB 570.53 ▲ 0.49% ADA 0.16 ▼ 1.23% DOGE 0.07 ▼ 0.40% AVAX 6.56 ▼ 0.30% LINK 8.30 ▲ 0.53% DOT 0.83 ▼ 1.99% LTC 45.98 ▲ 1.85% BCH 220.40 ▲ 0.30% TRX 0.32 ▲ 0.40% XLM 0.19 ▲ 0.47% HBAR 0.07 ▲ 1.03% NEAR 1.91 ▼ 0.75% ATOM 1.49 ▼ 1.36% AAVE 88.56 ▼ 1.55% SELIC 14.25% EMBRAER 81.75 ▼ 0.02% EMBRAER ADR 64.09 ▼ 0.44% JBS 11.91 ▼ 1.00% JBS BDR 60.20 ▼ 2.11% MBRF3 15.03 ▼ 1.70% MBRFY 2.90 ▼ 1.02% INTER 5.37 ▼ 3.07% EGX 52,928 ▲ 0.70% USD/ZAR 16.48 ▲ 0.63% USD/NGN 1,378 ▲ 0.02% NIKKEI 64,141 ▼ 4.03% CSI300 4,529 ▼ 3.60% HSI 24,562 ▼ 1.78% NIFTY 24,334 ▲ 1.09% KOSPI 6,821 ▼ 6.37% JCI 6,176 ▲ 1.10% USD/JPY 162.35 ▲ 0.01% USD/CNY 6.7768 ▲ 0.20% DAX 24,831 ▼ 0.34% CAC 8,339 ▼ 0.47% FTSE 10,600 ▲ 0.27% MIB 51,882 ▼ 0.94% IBEX 19,217 ▼ 0.45% STOXX 641.53 ▼ 0.34% EUR/USD 1.1446 ▲ 0.02% GBP/USD 1.3452 ▼ 0.21% SPX 7,458 ▼ 1.01% DJI 52,146 ▼ 0.77% NDX 28,593 ▼ 1.49% RUT 2,962 ▼ 0.42% TSX 35,264 ▼ 0.22% VIX 18.77 ▲ 12.19% USD/CAD 1.4020 ▼ 0.14% US10Y 4.5410 ▼ 0.61%
since 2009
Saturday, July 18, 2026

Pfizer had evidence of suppressed immune system from vaccination already early 2021 – documents

By · April 20, 2022 · 5 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

RIO DE JANEIRO, BRAZIL – In a 55,000-page set of documents released beginning or March 2022, the U.S. Food and Drug Administration’s (FDA’s) Center for Biologics Evaluation and Research (CBER) was for the first time allowing the public to access data Pfizer submitted to FDA from its clinical trials in support of a Covid-19 vaccine license.

This follows U.S. District Judge Mark T. Pittman’s decision on January 6 to deny the request from the FDA to suppress the data for the next 75 years, which the agency claimed was necessary, in part, because of its “limited resources.”

RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →

Read also: Check out our coverage on curated alternative narratives

As expected, the now significantly accelerated publication of Pfizer documents in the U.S. brings a steady stream of new findings – most of them anything but positive.

For example, a document published by the pharmaceutical giant on March 24, 2022, reveals that they were well aware of the immunosuppressive property of the mRNA vaccine against Covid-19.

The document is dated May 2021 and represents a request for “priority review” designation with the FDA – ultimately, for an expedited review by the agency.

In addition to noting that younger people are indeed increasingly affected by adverse reactions to the vaccine (i.e., those who are not at risk from Covid), it contains an exceedingly interesting paragraph:

“Clinical laboratory evaluations showed a transient decrease in lymphocytes that was observed in all age and dose groups after Dose 1, which resolved within approximately one week, were not associated with any other clinical sequelae, and were not considered clinically relevant.

Ribonucleic acid (RNA) vaccines are known to induce type I interferon, and type I interferons regulate lymphocyte recirculation and are associated with transient migration and/or redistribution of lymphocytes. This rapid rebound of lymphocytes supports that the lymphocytes are not depleted, but temporarily migrated out of the peripheral blood, and subsequently re-entered the bloodstream by the time of the next assessment.”

Source (pp. 8-9)

To summarize: Clinical laboratory studies have shown an alleged temporary decrease in lymphocytes in all age and dosage groups after the first vaccination (read: suppression of the immune system).

According to Pfizer, this is said to have regressed after one week. Ribonucleic acid (RNA) vaccines are known to induce type I interferon, which regulates lymphocyte recirculation and is associated with transient migration or redistribution of lymphocytes. The observed decrease in lymphocytes is not considered clinically relevant.

Experts and physicians worldwide now note that vaccination appears to result in longer-term dysregulation of the immune system. The consequences are not only flare-ups of viral infections but also a massive increase in cancer among vaccinated individuals.

So how should we evaluate the statement that the observation of a suppressed immune system immediately after vaccination is clinically “not relevant” (and accordingly probably not worthy of detailed research)?

The fact is that even a short-term impairment of the immune system can have severe consequences, especially for vulnerable groups. Pfizer’s study data already indicated that vaccinated individuals were more likely to contract covid shortly after the shot than unvaccinated individuals:

Suspected COVID-19 cases that occurred within seven days after any vaccination was 409 in the vaccine group vs. 287 in the placebo group.

Source (p. 41)

Pfizer blamed this on possible vaccine reactions, the symptoms of which were perhaps falsely attributed to Covid; however, this cannot be proven.

It is interesting to note that in the USA, as in Germany, vaccinees are generally not considered “vaccinated” until 14 days after their second dose – which means that a possible increase in Covid infections in the newly vaccinated could be attributed to the unvaccinated.

UNTOLD PFIZER STORY

It’s little wonder pharmaceutical giant Pfizer was the first to be granted permission to proceed with manufacturing experimental Covid vaccines for use in America. After all, they donated between US$1 million and US$5 million to the Clinton Foundation and spent a portion of its US$23.1 million in lobbying expenses from 2009 alone on issues at the Obama State Department.

Here a list of crimes of the enterprise which was allowed to produce Covid vaccines:

  • In 2009, Pfizer received the biggest fine in U.S. history as part of a US$2.3 Billion plea deal with federal prosecutors for mispromoting medicines (Bextra, Celebrex) and paying kickbacks to compliant doctors. Pfizer pleaded guilty to misbranding the painkiller Bextra by promoting the drug for uses for which it was not approved.
  • In the 1990s, Pfizer was involved in defective heart valves that led to the deaths of more than 100 people. Pfizer had deliberately misled regulators about the hazards. The company agreed to pay US$10.75 Million to settle justice department charges for misleading regulators.
  • Pfizer paid more than US$60 Million to settle a lawsuit over Rezulin, a diabetes medication that caused patients to die from acute liver failure.
  • In the UK, Pfizer has been fined nearly €90 Million for overcharging the NHS, the National Health Service. Pfizer charged the taxpayer an additional €48 Million per year for what should have cost €2 million per year.
  • Pfizer agreed to pay US$430 Million in 2004 to settle criminal charges that it had bribed doctors to prescribe its epilepsy drug Neurontin for indications for which it was not approved.
  • In 2011, a jury found Pfizer committed racketeering fraud in its marketing of the drug Neurontin. Pfizer agreed to pay US$142.1 Million to settle the charges.
  • Pfizer disclosed that it had paid nearly 4,500 doctors and other medical professionals some US$20 Million for speaking on Pfizer’s behalf.
  • In 2012, the U.S. Securities and Exchange Commission announced that it had reached a US$45 Million settlement with Pfizer to resolve charges that its subsidiaries had bribed overseas doctors and other healthcare professionals to increase foreign sales.
  • Pfizer was sued in a U.S. federal court for using Nigerian children as human guinea pigs, without the childrens’ parents’ consent. Pfizer paid US$75 Million to settle in Nigerian court for using an experimental antibiotic, Trovan, on the children.
  • The company paid an additional undisclosed amount in the U.S. to settle charges here. Pfizer had violated international law, including the Nuremberg Convention established after WWII, due to Nazi experiments on unwilling prisoners.

Amid widespread criticism of gouging poor countries for drugs, Pfizer pledged to give US$50 million for an AIDS drug to South Africa. Later, however, Pfizer failed to honor that promise.

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.